Limits...
Effect of targeted ovarian cancer therapy using amniotic fluid mesenchymal stem cells transfected with enhanced green fluorescent protein-human interleukin-2 in vivo.

You Q, Yao Y, Zhang Y, Fu S, Du M, Zhang G - Mol Med Rep (2015)

Bottom Line: The aim of the present study was to investigate the effect of using amniotic fluid mesenchymal stem cells (AF-MSCs) in targeted ovarian cancer therapy in vivo.AF-MSCs were isolated from human second trimester AF and a plasmid, enhanced green fluorescent protein‑human interleukin‑2 (pEGFP‑hIL‑2) was formed.It was found that AF‑MSCs exhibited high motility during migration in vivo, and the vector, pEGFP‑hIL‑2 can be stably transfected into AF‑MSCs.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynecology and Obstetrics, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.

ABSTRACT
The aim of the present study was to investigate the effect of using amniotic fluid mesenchymal stem cells (AF-MSCs) in targeted ovarian cancer therapy in vivo. AF-MSCs were isolated from human second trimester AF and a plasmid, enhanced green fluorescent protein‑human interleukin‑2 (pEGFP‑hIL‑2) was formed. The plasmid was stably transfected into the AF‑MSCs and the cells were intravenously injected into ovarian cancer nude mice models. Following stable transfection of the vector, tumor formation, and the expression and activity of hIL‑2 were investigated, and microscopic pathological examinations of the tumor were performed. It was found that AF‑MSCs exhibited high motility during migration in vivo, and the vector, pEGFP‑hIL‑2 can be stably transfected into AF‑MSCs. Following stable transfection, this type of stem cell is able to successfully transport the therapeutic gene, IL-2, migrate to the ovarian cancer tumor site to secrete the functional IL-2 and treat the tumor. Thus, AF-MSCs may serve as transporters for therapeutic genes targeting ovarian tumor sites and, therefore, be involved in the treatment of tumors.

Show MeSH

Related in: MedlinePlus

Transmission electron microscopic observation of apoptosis in SKOV3 cells (magnification, ×4,000). (A) Apoptotic SKOV3 cell displaying a swollen endoplasmic reticulum and (B) SKOV3 cell from the control group (magnification, ×4,000).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4581758&req=5

f14-mmr-12-04-4859: Transmission electron microscopic observation of apoptosis in SKOV3 cells (magnification, ×4,000). (A) Apoptotic SKOV3 cell displaying a swollen endoplasmic reticulum and (B) SKOV3 cell from the control group (magnification, ×4,000).

Mentions: The ovarian cancer tissue of the treatment group (nude mice that were injected with the pEGFP-hIL-2 recombined plasmid) was fixed using glutaraldehyde, and the ultrastructure of SKOV3 ovarian cancer cells was observed under a transmission electron microscope. The reductus of the nuclear membrane was observed to be depressed, chromatin was condensed, more compact, concentrated and parted, and there were more layers of endoplasmic reticulum surrounding the nucleus. Furthermore, the endoplasmic reticulum had become swollen and expanded, as shown in Fig. 14A. The ultrastructure of the ovarian cancer cells from the untreated group (observed by transmission electron microscope) are presented in Fig. 14B.


Effect of targeted ovarian cancer therapy using amniotic fluid mesenchymal stem cells transfected with enhanced green fluorescent protein-human interleukin-2 in vivo.

You Q, Yao Y, Zhang Y, Fu S, Du M, Zhang G - Mol Med Rep (2015)

Transmission electron microscopic observation of apoptosis in SKOV3 cells (magnification, ×4,000). (A) Apoptotic SKOV3 cell displaying a swollen endoplasmic reticulum and (B) SKOV3 cell from the control group (magnification, ×4,000).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4581758&req=5

f14-mmr-12-04-4859: Transmission electron microscopic observation of apoptosis in SKOV3 cells (magnification, ×4,000). (A) Apoptotic SKOV3 cell displaying a swollen endoplasmic reticulum and (B) SKOV3 cell from the control group (magnification, ×4,000).
Mentions: The ovarian cancer tissue of the treatment group (nude mice that were injected with the pEGFP-hIL-2 recombined plasmid) was fixed using glutaraldehyde, and the ultrastructure of SKOV3 ovarian cancer cells was observed under a transmission electron microscope. The reductus of the nuclear membrane was observed to be depressed, chromatin was condensed, more compact, concentrated and parted, and there were more layers of endoplasmic reticulum surrounding the nucleus. Furthermore, the endoplasmic reticulum had become swollen and expanded, as shown in Fig. 14A. The ultrastructure of the ovarian cancer cells from the untreated group (observed by transmission electron microscope) are presented in Fig. 14B.

Bottom Line: The aim of the present study was to investigate the effect of using amniotic fluid mesenchymal stem cells (AF-MSCs) in targeted ovarian cancer therapy in vivo.AF-MSCs were isolated from human second trimester AF and a plasmid, enhanced green fluorescent protein‑human interleukin‑2 (pEGFP‑hIL‑2) was formed.It was found that AF‑MSCs exhibited high motility during migration in vivo, and the vector, pEGFP‑hIL‑2 can be stably transfected into AF‑MSCs.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynecology and Obstetrics, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.

ABSTRACT
The aim of the present study was to investigate the effect of using amniotic fluid mesenchymal stem cells (AF-MSCs) in targeted ovarian cancer therapy in vivo. AF-MSCs were isolated from human second trimester AF and a plasmid, enhanced green fluorescent protein‑human interleukin‑2 (pEGFP‑hIL‑2) was formed. The plasmid was stably transfected into the AF‑MSCs and the cells were intravenously injected into ovarian cancer nude mice models. Following stable transfection of the vector, tumor formation, and the expression and activity of hIL‑2 were investigated, and microscopic pathological examinations of the tumor were performed. It was found that AF‑MSCs exhibited high motility during migration in vivo, and the vector, pEGFP‑hIL‑2 can be stably transfected into AF‑MSCs. Following stable transfection, this type of stem cell is able to successfully transport the therapeutic gene, IL-2, migrate to the ovarian cancer tumor site to secrete the functional IL-2 and treat the tumor. Thus, AF-MSCs may serve as transporters for therapeutic genes targeting ovarian tumor sites and, therefore, be involved in the treatment of tumors.

Show MeSH
Related in: MedlinePlus